Debbie Etchison - Scynexis Executive Communications
| SCYX Stock | USD 1.32 0.05 3.65% |
Executive
Debbie Etchison is Executive Communications of Scynexis
| Address | 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 |
| Phone | 201 884 5485 |
| Web | https://www.scynexis.com |
Scynexis Management Efficiency
The company has return on total asset (ROA) of (0.2672) % which means that it has lost $0.2672 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4842) %, meaning that it created substantial loss on money invested by shareholders. Scynexis' management efficiency ratios could be used to measure how well Scynexis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.55 in 2024. Return On Capital Employed is likely to rise to 0.68 in 2024. At this time, Scynexis' Non Current Assets Total are fairly stable compared to the past year. Other Assets is likely to rise to about 9.2 M in 2024, whereas Total Assets are likely to drop slightly above 70.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Davis | Ironwood Pharmaceuticals | 38 | |
| Thomas Pearl | Organogenesis Holdings | N/A | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Jennifer Henry | Alpha Teknova | N/A | |
| Todd Anthony | Cumberland Pharmaceuticals | 63 | |
| Ori Gutwerg | ANI Pharmaceuticals | 50 | |
| Kristen JD | Pacira BioSciences, | 50 | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Huang CFA | China Pharma Holdings | N/A | |
| Liron Reshef | Kamada | 53 | |
| Chris Bitterman | Cumberland Pharmaceuticals | 59 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Christopher Mutz | ANI Pharmaceuticals | 53 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Christopher Young | Pacira BioSciences, | 52 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Samantha Widdicombe | Biofrontera | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.27 |
Scynexis Leadership Team
Elected by the shareholders, the Scynexis' board of directors comprises two types of representatives: Scynexis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scynexis. The board's role is to monitor Scynexis' management team and ensure that shareholders' interests are well served. Scynexis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scynexis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Debbie Etchison, Executive Communications | ||
| Scott JD, Chief Secretary | ||
| Marco MD, Pres CEO | ||
| Daniella Gigante, Vice Technology | ||
| Christine MBA, Chief Officer | ||
| David MD, Chief Officer |
Scynexis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scynexis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (15.64) % | ||||
| Current Valuation | (2.84 M) | ||||
| Shares Outstanding | 37.94 M | ||||
| Shares Owned By Insiders | 1.10 % | ||||
| Shares Owned By Institutions | 44.38 % | ||||
| Number Of Shares Shorted | 837.55 K | ||||
| Price To Earning | (1.90) X | ||||
| Price To Book | 0.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Scynexis Stock Analysis
When running Scynexis' price analysis, check to measure Scynexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scynexis is operating at the current time. Most of Scynexis' value examination focuses on studying past and present price action to predict the probability of Scynexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scynexis' price. Additionally, you may evaluate how the addition of Scynexis to your portfolios can decrease your overall portfolio volatility.